<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20241001141403&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;ff=20241001141403&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 01 Oct 2024 18:14:04 +0000</lastbuilddate>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Aficamten in Hypertrophic Cardiomyopathy: Roots and Branches of SEQUOIA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352342/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08395-5. doi: 10.1016/j.jacc.2024.08.064. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352342/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39352342</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.064>10.1016/j.jacc.2024.08.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352342</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aficamten in Hypertrophic Cardiomyopathy: Roots and Branches of SEQUOIA</dc:title>
<dc:identifier>pmid:39352342</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.064</dc:identifier>
</item>
<item>
<title>Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes, or Is it Placebo?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08519-X. doi: 10.1016/j.jacc.2024.09.021. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39352341</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.021>10.1016/j.jacc.2024.09.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352341</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Torsten B Rasmussen</dc:creator>
<dc:creator>Anne M Dybro</dc:creator>
<dc:creator>Morten Kvistholm Jensen</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes, or Is it Placebo?</dc:title>
<dc:identifier>pmid:39352341</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.021</dc:identifier>
</item>
<item>
<title>Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352340/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compared with those without recent WHF, patients with HF and mildly reduced or preserved ejection fraction who have experienced a recent WHF event are at higher risk for recurrent HF events and CV death; a possible signal of enhanced absolute treatment benefit with finerenone in this population requires further confirmation in future studies. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] &amp; Mortality...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08452-3. doi: 10.1016/j.jacc.2024.09.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure (HF) and a recent worsening heart failure (WHF) event are known to be at high risk of recurrent hospitalization and death, regardless of ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study examined the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone in relation to the recency of a WHF event.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure) was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction ≥40%. In this prespecified analysis, we assessed the risk of cardiovascular (CV) events and response to finerenone vs placebo in relation to the time from WHF to randomization (during or within 7 days, 7 days to 3 months, >;3 months, or no prior WHF). The primary outcome was a composite of total (first and recurrent) WHF events and CV death, analyzed using a proportional rates method.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 6,001 patients validly randomized to finerenone or placebo, 1,219 (20.3%) were enrolled during (749 [12.5%]) or within 7 days (470 [7.8%]), 2,028 (33.8%) between 7 days and 3 months, and 937 (15.6%) >;3 months from a WHF event; 1,817 (30.3%) had no prior history of WHF. Rates of the primary composite outcome varied inversely with time since WHF, with >;2-fold higher risk in those enrolled during or within 7 days of WHF compared with those enrolled >;3 months from WHF or without prior WHF (risk ratio [RR]: 2.13; 95% CI: 1.82-2.55). Compared to placebo, finerenone appeared to lower the risk of the primary composite to a greater extent in those enrolled within 7 days of WHF (RR: 0.74; 95% CI: 0.57-0.95) or between 7 days and 3 months of WHF (RR: 0.79; 95% CI: 0.64-0.97) than in those >;3 months from WHF or without prior WHF (RR: 0.99; 95% CI: 0.81-1.21); however, no definitive treatment-by-time interaction could be confirmed (P = 0.07). Greater absolute risk reductions with finerenone were accordingly seen in those with recent WHF (P<sub>trend</sub> = 0.011). The risk of adverse events including hyperkalemia and worsening renal function among patients assigned to finerenone was not increased in those with recent WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared with those without recent WHF, patients with HF and mildly reduced or preserved ejection fraction who have experienced a recent WHF event are at higher risk for recurrent HF events and CV death; a possible signal of enhanced absolute treatment benefit with finerenone in this population requires further confirmation in future studies. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] &amp; Mortality [Death Rate] in Participants With Heart Failure and Left Ventricular Ejection Fraction [Proportion of Blood Expelled Per Heart Stroke] Greater or Equal to 40% [FINEARTS-HF], NCT04435626; A study to gather information on the influence of study drug finerenone on the number of deaths and hospitalizations in participants with heart failure EudraCT 2020-000306-29).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352340/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39352340</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.004>10.1016/j.jacc.2024.09.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352340</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Jonathan Cunningham</dc:creator>
<dc:creator>Maria Borentain</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Katja Rohwedder</dc:creator>
<dc:creator>Flaviana Amarante</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Mikhail Kosiborod</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial</dc:title>
<dc:identifier>pmid:39352340</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.004</dc:identifier>
</item>
<item>
<title>Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352339/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08386-4. doi: 10.1016/j.jacc.2024.09.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This responder analysis from the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) trial characterizes the clinical impact of aficamten.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients who were symptomatic of oHCM were randomized to aficamten (n = 142) or placebo (n = 140) daily for 24 weeks. Outcomes assessed included the proportion of patients with complete hemodynamic response (rest and Valsalva gradient &lt;30 mm Hg and &lt;50 mm Hg, respectively), relief in limiting symptoms (≥1 improvement in NYHA functional class and/or ≥10-point change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score), enhanced exercise capacity (≥1.5 mL/kg/min change in peak oxygen uptake), and ≥50% reduction in N-terminal pro-B-type natriuretic peptide. Eligibility for septal reduction therapy was also evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 24 weeks, patients treated with aficamten vs placebo showed significant improvement in limiting symptoms (71% vs 42%), were more likely to have complete hemodynamic response (68% vs 7%), demonstrated enhanced exercise capacity (47% vs 24%), and showed a decrease ≥50% in N-terminal pro-B-type natriuretic peptide (84% vs 8%) (P ≤ 0.002 for all). An improvement in ≥1 of these outcome measures was achieved in 97% of patients treated with aficamten (vs 59% placebo), including 23% on aficamten who achieved all 4 outcomes compared with none in placebo. Among 32 patients receiving aficamten and 29 patients receiving placebo who were eligible for septal reduction therapy, 28 (88%) from the aficamten group were no longer eligible at 24 weeks compared with 15 (52%) from the placebo group (P = 0.002).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352339/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39352339</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.003>10.1016/j.jacc.2024.09.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352339</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Michael E Nassif</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>Michael Arad</dc:creator>
<dc:creator>Nuno Cardim</dc:creator>
<dc:creator>Lubna Choudhury</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Caroline J Coats</dc:creator>
<dc:creator>Hans-Dirk Düngen</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Albert A Hagège</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Ian Kulac</dc:creator>
<dc:creator>Matthew M Y Lee</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Chang-Sheng Ma</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Artur Oreziak</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Jacob Tfelt-Hansen</dc:creator>
<dc:creator>Marion van Sinttruije</dc:creator>
<dc:creator>Josef Veselka</dc:creator>
<dc:creator>Hugh C Watkins</dc:creator>
<dc:creator>Daniel L Jacoby</dc:creator>
<dc:creator>Stephen B Heitner</dc:creator>
<dc:creator>Stuart Kupfer</dc:creator>
<dc:creator>Fady I Malik</dc:creator>
<dc:creator>Lisa Meng</dc:creator>
<dc:creator>Amy Wohltman</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>SEQUOIA-HCM Investigators</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM</dc:title>
<dc:identifier>pmid:39352339</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.003</dc:identifier>
</item>
<item>
<title>Time to Significant Benefit of Finerenone in Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39352338/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 26:S0735-1097(24)08512-7. doi: 10.1016/j.jacc.2024.09.018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39352338/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39352338</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.018>10.1016/j.jacc.2024.09.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39352338</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Time to Significant Benefit of Finerenone in Patients With Heart Failure</dc:title>
<dc:identifier>pmid:39352338</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.018</dc:identifier>
</item>
<item>
<title>Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Aldosterone concentration and aldosterone-to-renin ratio were positively associated with the LVMI in young males and females, respectively, independently of systolic blood pressure. Long-term follow-up is required to determine whether the relationship persists over time, and clinical trials are needed to assess the cardiovascular benefits of early interventions to block aldosterone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 1. doi: 10.1161/CIRCULATIONAHA.124.070039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Primary aldosteronism, characterized by renin-independent aldosterone production, is associated with adverse cardiovascular remodeling and outcomes. Elevated cardiovascular risk is observed even in subclinical forms of primary aldosteronism according to studies conducted primarily in middle-aged and elderly populations. This study aimed to assess whether early changes in primary aldosteronism biomarkers during young adulthood are associated with arterial stiffness and left ventricular mass index (LVMI) before the onset of overt disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Raine Study is a longitudinal, population-based cohort study in Western Australia that enrolled women during pregnancy. We analyzed the data from the offspring of these women at 17 (2006-2009) and 27 (2016-2018) years of age. Participants with elevated high-sensitivity C-reactive protein (>;10 mg/L) and female participants who were on oral contraception were excluded. Pulse wave velocity and aortic augmentation index were measured by SphygmoCor Pulse Wave System at both ages, and aortic distensibility and LVMI were measured by cardiac magnetic resonance imaging at 27 years. Multivariable linear regression was used to examine the relationship between plasma renin, aldosterone, or aldosterone-to-renin ratio and arterial stiffness and LVMI. Mediation analysis was used to test the role of systolic blood pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 859 participants at 17 (38.0% female) and 758 participants at 27 (33.2% female) years of age. Females had lower renin concentration at both 17 (20.7 mU/L versus 25.7 mU/L; <i>P</i>&lt;0.001) and 27 (12.0 mU/L versus 15.4 mU/L; <i>P</i>&lt;0.001) years of age; hence, the aldosterone-to-renin ratio was significantly higher at both 17 (18.2 versus 13.5; <i>P</i>&lt;0.001) and 27 (21.0 versus 15.6; <i>P</i>&lt;0.001) years of age in females compared with males. At 27 years of age, a significant association was detected between aldosterone and LVMI in males (β=0.009 [95% CI, 0.001-0.017]; <i>P</i>=0.027) and between aldosterone-to-renin ratio and LVMI in females (β=0.098 [95% CI, 0.001-0.196]; <i>P</i>=0.050) independently of systolic blood pressure and other confounders. No association was found between primary aldosteronism biomarkers and measures of arterial stiffness (pulse wave velocity, aortic augmentation index, and aortic distensibility) at either age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Aldosterone concentration and aldosterone-to-renin ratio were positively associated with the LVMI in young males and females, respectively, independently of systolic blood pressure. Long-term follow-up is required to determine whether the relationship persists over time, and clinical trials are needed to assess the cardiovascular benefits of early interventions to block aldosterone.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39351674</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070039>10.1161/CIRCULATIONAHA.124.070039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351674</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Roshan A Ananda</dc:creator>
<dc:creator>StellaMay Gwini</dc:creator>
<dc:creator>Lawrence J Beilin</dc:creator>
<dc:creator>Markus P Schlaich</dc:creator>
<dc:creator>Michael Stowasser</dc:creator>
<dc:creator>Morag J Young</dc:creator>
<dc:creator>Brendan Adler</dc:creator>
<dc:creator>Peter J Fuller</dc:creator>
<dc:creator>Trevor A Mori</dc:creator>
<dc:creator>Jun Yang</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relationship Between Renin, Aldosterone, Aldosterone-to-Renin Ratio and Arterial Stiffness and Left Ventricular Mass Index in Young Adults</dc:title>
<dc:identifier>pmid:39351674</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070039</dc:identifier>
</item>
<item>
<title>Pneumonia Induced Rise in Glucagon Promotes Endothelial Damage and Thrombogenicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 1. doi: 10.1161/CIRCRESAHA.124.324938. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39351669</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324938>10.1161/CIRCRESAHA.124.324938</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351669</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pegah Ramezani Rad</dc:creator>
<dc:creator>Vanasa Nageswaran</dc:creator>
<dc:creator>Lisa Peters</dc:creator>
<dc:creator>Leander Reinshagen</dc:creator>
<dc:creator>Johann Roessler</dc:creator>
<dc:creator>Szandor Simmons</dc:creator>
<dc:creator>Erik Asmus</dc:creator>
<dc:creator>Corey Wittig</dc:creator>
<dc:creator>Markus C Brack</dc:creator>
<dc:creator>Geraldine Nouailles</dc:creator>
<dc:creator>Emiel P C van der Vorst</dc:creator>
<dc:creator>Sanne L Maas</dc:creator>
<dc:creator>Kristina Sonnenschein</dc:creator>
<dc:creator>Barbara Verhaar</dc:creator>
<dc:creator>Robert Szulcek</dc:creator>
<dc:creator>Martin Witzenrath</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Wolfgang M Kuebler</dc:creator>
<dc:creator>Arash Haghikia</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Pneumonia Induced Rise in Glucagon Promotes Endothelial Damage and Thrombogenicity</dc:title>
<dc:identifier>pmid:39351669</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324938</dc:identifier>
</item>
<item>
<title>Transformation of the Kidney into a Pathological Neuro-Immune-Endocrine Organ</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39351666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 1. doi: 10.1161/CIRCRESAHA.124.325305. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39351666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39351666</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325305>10.1161/CIRCRESAHA.124.325305</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39351666</guid>
<pubDate>Tue, 01 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Manako Yamaguchi</dc:creator>
<dc:creator>Lucas Ferreira de Almeida</dc:creator>
<dc:creator>Hiroki Yamaguchi</dc:creator>
<dc:creator>Xiuyin Liang</dc:creator>
<dc:creator>Jason P Smith</dc:creator>
<dc:creator>Silvia Medrano</dc:creator>
<dc:creator>Maria Luisa S Sequeira Lopez</dc:creator>
<dc:creator>R Ariel Gomez</dc:creator>
<dc:date>2024-10-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Transformation of the Kidney into a Pathological Neuro-Immune-Endocrine Organ</dc:title>
<dc:identifier>pmid:39351666</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325305</dc:identifier>
</item>
<item>
<title>Unveiling the Hidden Layers of Hypertensive Heart Disease Through Quantitative PET Imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1087-1089. doi: 10.1161/CIRCULATIONAHA.124.071479. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39348457</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071479>10.1161/CIRCULATIONAHA.124.071479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348457</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Andreas A Giannopoulos</dc:creator>
<dc:creator>Alessia Gimelli</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unveiling the Hidden Layers of Hypertensive Heart Disease Through Quantitative PET Imaging</dc:title>
<dc:identifier>pmid:39348457</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071479</dc:identifier>
</item>
<item>
<title>Prescribing a New Treatment in Heart Disease Communication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1070-1071. doi: 10.1161/CIRCULATIONAHA.124.069581. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39348456</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069581>10.1161/CIRCULATIONAHA.124.069581</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348456</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Wyatt G Paltzer</dc:creator>
<dc:creator>Dietram A Scheufele</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prescribing a New Treatment in Heart Disease Communication</dc:title>
<dc:identifier>pmid:39348456</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069581</dc:identifier>
</item>
<item>
<title>Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348455/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1072-1074. doi: 10.1161/CIRCULATIONAHA.124.070525. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348455/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39348455</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070525>10.1161/CIRCULATIONAHA.124.070525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348455</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Lathan Liou</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Amy R Kontorovich</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv Amyloidosis</dc:title>
<dc:identifier>pmid:39348455</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070525</dc:identifier>
</item>
<item>
<title>Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1151-1153. doi: 10.1161/CIRCULATIONAHA.124.070347. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39348454</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070347>10.1161/CIRCULATIONAHA.124.070347</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348454</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter R Sinnaeve</dc:creator>
<dc:creator>Robert C Welsh</dc:creator>
<dc:creator>Alexandra Arias Mendoza</dc:creator>
<dc:creator>Arsen D Ristić</dc:creator>
<dc:creator>Oleg V Averkov</dc:creator>
<dc:creator>Yves Lambert</dc:creator>
<dc:creator>José F Kerr Saraiva</dc:creator>
<dc:creator>Pablo Sepulveda</dc:creator>
<dc:creator>Fernando Rosell-Ortiz</dc:creator>
<dc:creator>John K French</dc:creator>
<dc:creator>Ljilja B Musić</dc:creator>
<dc:creator>Katleen Vandenberghe</dc:creator>
<dc:creator>Kris Bogaerts</dc:creator>
<dc:creator>Thierry Danays</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Paul W Armstrong</dc:creator>
<dc:creator>Frans Van de Werf</dc:creator>
<dc:creator>STREAM-2 Investigators</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up</dc:title>
<dc:identifier>pmid:39348454</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070347</dc:identifier>
</item>
<item>
<title>Coronary Artery Bypass Grafting: Past and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39348453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct;150(14):1067-1069. doi: 10.1161/CIRCULATIONAHA.124.068312. Epub 2024 Sep 30.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39348453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39348453</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068312>10.1161/CIRCULATIONAHA.124.068312</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39348453</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>Joanna Chikwe</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Coronary Artery Bypass Grafting: Past and Future</dc:title>
<dc:identifier>pmid:39348453</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068312</dc:identifier>
</item>
<item>
<title>Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39347697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In an open-label trial in patients with HFpEF with LVEF of 60% or greater, mavacamten was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF observed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 30. doi: 10.1001/jamacardio.2024.3810. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Patients with heart failure with preserved ejection fraction (HFpEF) who have left ventricular ejection fraction (LVEF) of 60% or greater have limited treatment options.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the effects of cardiac myosin inhibition with mavacamten in patients with HFpEF with LVEF of 60% or greater.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The EMBARK-HFpEF trial was a phase 2a, open-label, single-arm, multicenter trial conducted from November 6, 2020, to February 26, 2024, at 20 sites in the US and Canada. Patients with symptomatic HFpEF (defined as a New York Heart Association [NYHA] functional class II or III), LVEF of 60% or greater, elevated N-terminal pro-B-type natriuretic peptide (NTproBNP), and left ventricular hypertrophy were eligible for inclusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Mavacamten treatment for 26 weeks, starting at 2.5 mg and potentially titrated up to 5 mg at week 14 based on prespecified LVEF and NTproBNP criteria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Primary efficacy end points (measured as the change from baseline to week 26) included NTproBNP and high-sensitivity troponin T (hsTnT); additional efficacy end points included changes in high-sensitivity troponin I (hsTnI), NYHA functional class, and echocardiographic parameters (resting and peak exercise). Safety end points included treatment-emergent adverse events and reductions in LVEF to less than 30%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 30 patients were enrolled and treated with mavacamten. Median (IQR) patient age was 76 (70-80) years, and 16 patients (53.3%) were female. From baseline to week 26, mavacamten was associated with reductions in NTproBNP (mean reduction, -26%; 95% CI, -44% to -4%; P = .04), hsTnT (mean reduction, -13%; 95% CI, -23% to -3%; P = .02), and hsTnI (mean reduction, -20%; 95% CI, -32% to -6%; P = .01). Cardiac biomarker values returned toward baseline levels 8 weeks after drug discontinuation. NYHA class improved in 10 of 24 patients (41.7%) who had evaluable NYHA class data at the end of treatment, and improvements in echocardiographic markers of LV diastolic function were observed. Mean LVEF decreased by 3.2 absolute percentage points (95% CI, 1.1-5.4; P = .005) during treatment. Mavacamten was interrupted in 3 patients (10% of the study population; 95% CI, 2.1%-26.5%) due to protocol prespecified criteria of LVEF less than 50% (n = 2) or a more than 20% relative decrease from baseline (n = 1; nadir LVEF, 58%), with LVEF recovery observed in all 3 patients. There were no deaths or instances of LVEF less than 30%; 1 patient had worsening heart failure deemed unrelated to the study drug.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In an open-label trial in patients with HFpEF with LVEF of 60% or greater, mavacamten was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in LVEF observed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04766892.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39347697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39347697</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3810>10.1001/jamacardio.2024.3810</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39347697</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Marzia Rigolli</dc:creator>
<dc:creator>Atefeh Javidialsaadi</dc:creator>
<dc:creator>Ravi B Patel</dc:creator>
<dc:creator>Suhail Khadra</dc:creator>
<dc:creator>Parag Goyal</dc:creator>
<dc:creator>Sean Little</dc:creator>
<dc:creator>Omar Wever-Pinzon</dc:creator>
<dc:creator>Anjali Tiku Owens</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Pankaj Arora</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial</dc:title>
<dc:identifier>pmid:39347697</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3810</dc:identifier>
</item>
<item>
<title>Mucolipidosis III: a rare phenocopy of inherited metabolic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39344930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 30:ehae636. doi: 10.1093/eurheartj/ehae636. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39344930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39344930</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae636>10.1093/eurheartj/ehae636</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39344930</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xia Gu</dc:creator>
<dc:creator>Linlin Dai</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mucolipidosis III: a rare phenocopy of inherited metabolic cardiomyopathy</dc:title>
<dc:identifier>pmid:39344930</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae636</dc:identifier>
</item>
<item>
<title>Fusion mixed reality: a novel approach to merge the physical and virtual cath lab</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39344929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 30:ehae632. doi: 10.1093/eurheartj/ehae632. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39344929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39344929</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae632>10.1093/eurheartj/ehae632</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39344929</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>João Silva Marques</dc:creator>
<dc:creator>Catarina Oliveira</dc:creator>
<dc:creator>Fausto J Pinto</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fusion mixed reality: a novel approach to merge the physical and virtual cath lab</dc:title>
<dc:identifier>pmid:39344929</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae632</dc:identifier>
</item>
<item>
<title>Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39344920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 30:ehae639. doi: 10.1093/eurheartj/ehae639. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: While the rationale for coronavirus disease 2019 (COVID-19) vaccination is to reduce complications and overall mortality, some cardiovascular complications from the vaccine itself have been demonstrated. Myocarditis and pericarditis are recognized as rare acute adverse events after mRNA vaccines in young males, while evidence regarding other cardiovascular events remains limited and inconsistent. This study assessed the risks of several cardiovascular and cerebrovascular events in a Swedish nationwide register-based cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Post-vaccination risk of myocarditis/pericarditis, dysrhythmias, heart failure, myocardial infarction, and cerebrovascular events (transient ischaemic attack and stroke) in several risk windows after each vaccine dose were assessed among all Swedish adults (n = 8 070 674). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) compared with unvaccinated were estimated from Cox regression models adjusted for potential confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For most studied outcomes, decreased risks of cardiovascular events post-vaccination were observed, especially after dose three (HRs for dose three ranging from .69 to .81), while replicating the increased risk of myocarditis and pericarditis 1-2 weeks after COVID-19 mRNA vaccination. Slightly increased risks, similar across vaccines, were observed for extrasystoles [HR 1.17 (95% CI 1.06-1.28) for dose one and HR 1.22 (95% CI 1.10-1.36) for dose two, stronger in elderly and males] but not for arrhythmias and for transient ischaemic attack [HR 1.13 (95% CI 1.05-1.23), mainly in elderly] but not for stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39344920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39344920</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae639>10.1093/eurheartj/ehae639</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39344920</guid>
<pubDate>Mon, 30 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yiyi Xu</dc:creator>
<dc:creator>Huiqi Li</dc:creator>
<dc:creator>Ailiana Santosa</dc:creator>
<dc:creator>Björn Wettermark</dc:creator>
<dc:creator>Tove Fall</dc:creator>
<dc:creator>Jonas Björk</dc:creator>
<dc:creator>Mats Börjesson</dc:creator>
<dc:creator>Magnus Gisslén</dc:creator>
<dc:creator>Fredrik Nyberg</dc:creator>
<dc:date>2024-09-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study</dc:title>
<dc:identifier>pmid:39344920</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae639</dc:identifier>
</item>
<item>
<title>Clinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: Results From the Multicenter SAFE MRI ECMO Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39342513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study demonstrates that ULF-pMRI can be performed in patients on ECMO across different ECMO cannulation strategies in specially trained intensive care units. The incidence of ABI was high, seen in 44% of ULF-pMRI studies. ULF-pMRI imaging appears to be more sensitive to ABI, particularly ischemic stroke, compared with head computed tomography.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.069187. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Early detection of acute brain injury (ABI) at the bedside is critical in improving survival for patients with extracorporeal membrane oxygenation (ECMO) support. We aimed to examine the safety of ultra-low-field (ULF; 0.064-T) portable magnetic resonance imaging (pMRI) in patients undergoing ECMO and to investigate the ABI frequency and types with ULF-pMRI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a multicenter prospective observational study (SAFE MRI ECMO study [Assessing the Safety and Feasibility of Bedside Portable Low-Field Brain Magnetic Resonance Imaging in Patients on ECMO]; NCT05469139) from 2 tertiary centers (Johns Hopkins, Baltimore, MD and University of Texas-Houston) with specially trained intensive care units. Primary outcomes were safety of ULF-pMRI during ECMO support, defined as completion of ULF-pMRI without significant adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 53 eligible patients, 3 were not scanned because of a large head size that did not fit within the head coil. ULF-pMRI was performed in 50 patients (median age, 58 years; 52% male), with 34 patients (68%) on venoarterial ECMO and 16 patients (32%) on venovenous ECMO. Of 34 patients on venoarterial ECMO, 11 (22%) were centrally cannulated and 23 (46%) were peripherally cannulated. In venovenous ECMO, 9 (18%) had single-lumen cannulation and 7 (14%) had double-lumen cannulation. Of 50 patients, adverse events occurred in 3 patients (6%), with 2 minor adverse events (ECMO suction event; transient low ECMO flow) and one serious adverse event (intra-aortic balloon pump malfunction attributable to electrocardiographic artifacts). All images demonstrated discernible intracranial pathologies with good quality. ABI was observed in 22 patients (44%). Ischemic stroke (36%) was the most common type of ABI, followed by intracranial hemorrhage (6%) and hypoxic-ischemic brain injury (4%). Of 18 patients (36%) with both ULF-pMRI and head computed tomography within 24 hours, ABI was observed in 9 patients with a total of 10 events (8 ischemic, 2 hemorrhagic events). Of the 8 ischemic events, pMRI observed all 8, and head computed tomography observed only 4 events. For intracranial hemorrhage, pMRI observed only 1 of them, and head computed tomography observed both (2 events).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study demonstrates that ULF-pMRI can be performed in patients on ECMO across different ECMO cannulation strategies in specially trained intensive care units. The incidence of ABI was high, seen in 44% of ULF-pMRI studies. ULF-pMRI imaging appears to be more sensitive to ABI, particularly ischemic stroke, compared with head computed tomography.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39342513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39342513</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069187>10.1161/CIRCULATIONAHA.124.069187</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39342513</guid>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sung-Min Cho</dc:creator>
<dc:creator>Shivalika Khanduja</dc:creator>
<dc:creator>Christopher Wilcox</dc:creator>
<dc:creator>Kha Dinh</dc:creator>
<dc:creator>Jiah Kim</dc:creator>
<dc:creator>Jin Kook Kang</dc:creator>
<dc:creator>Ifeanyi David Chinedozi</dc:creator>
<dc:creator>Zachary Darby</dc:creator>
<dc:creator>Matthew Acton</dc:creator>
<dc:creator>Hannah Rando</dc:creator>
<dc:creator>Jessica Briscoe</dc:creator>
<dc:creator>Errol L Bush</dc:creator>
<dc:creator>Haris I Sair</dc:creator>
<dc:creator>John Pitts</dc:creator>
<dc:creator>Lori R Arlinghaus</dc:creator>
<dc:creator>Audrey-Carelle N Wandji</dc:creator>
<dc:creator>Elena Moreno</dc:creator>
<dc:creator>Glenda Torres</dc:creator>
<dc:creator>Bindu Akkanti</dc:creator>
<dc:creator>Jose Gavito-Higuera</dc:creator>
<dc:creator>Steven Keller</dc:creator>
<dc:creator>HuiMahn A Choi</dc:creator>
<dc:creator>Bo Soo Kim</dc:creator>
<dc:creator>Aaron Gusdon</dc:creator>
<dc:creator>Glenn J Whitman</dc:creator>
<dc:creator>SAFE MRI ECMO Investigators</dc:creator>
<dc:date>2024-09-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: Results From the Multicenter SAFE MRI ECMO Study</dc:title>
<dc:identifier>pmid:39342513</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069187</dc:identifier>
</item>
<item>
<title>Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39342512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HFmrEF/HFpEF, finerenone reduced the risk of cardiovascular death and worsening heart failure events, irrespective of LVEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The effect of treatments for heart failure may vary among patients according to left ventricular ejection fraction (LVEF). In the FINEARTS-HF, the nonsteroidal MRA finerenone reduced the risk of cardiovascular death and total worsening heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). We examined the effect of finerenone according to LVEF in FINEARTS-HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FINEARTS-HF was a randomized, placebo-controlled trial examining the efficacy and safety of finerenone in patients with heart failure and LVEF &amp;#x226540%. The treatment effect of finerenone was examined in prespecified analyses according to LVEF categories (&lt;50%, ≥50 to &lt;60%, and ≥60%) and with LVEF as a continuous variable. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Baseline LVEF data were available for 5993 of the 6001 participants in FINEARTS-HF. Mean and median LVEF were 53 ± 8% and 53% (IQR 46% -58%), respectively. LVEF was &lt;50% in 2172 (36), between 50 to &lt;60% in 2674 (45%), and ≥60% in 1147 (19%). Patients with a higher LVEF were older, more commonly female, were less likely to have a history of coronary artery disease, and more frequently had a history of hypertension and chronic kidney disease compared to those with a lower LVEF. Finerenone reduced the risk of cardiovascular death and total heart failure events consistently across LVEF categories: LVEF &lt;50% rate ratio (RR) = 0.84 (95% CI 0.68, 1.03), LVEF ≥50 to &lt;60% RR = 0.80 (0.66, 0.97) and LVEF ≥60% RR = 0.94 (0.70, 1.25); p interaction = 0.70. There was no modification of the benefit of finerenone across the range of LVEF when analyzed as a continuous variable (p interaction = 0.28). There was a similar consistent effect of finerenone on reducing the total number of worsening heart failure events (continuous p interaction = 0.26).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFmrEF/HFpEF, finerenone reduced the risk of cardiovascular death and worsening heart failure events, irrespective of LVEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39342512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39342512</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072011>10.1161/CIRCULATIONAHA.124.072011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39342512</guid>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Katharina Mueller</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Andrea Scalise</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:date>2024-09-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial</dc:title>
<dc:identifier>pmid:39342512</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072011</dc:identifier>
</item>
<item>
<title>New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39342493/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 29;45(36):3299-3302. doi: 10.1093/eurheartj/ehae638.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39342493/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39342493</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae638>10.1093/eurheartj/ehae638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39342493</guid>
<pubDate>Sun, 29 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-09-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies</dc:title>
<dc:identifier>pmid:39342493</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae638</dc:identifier>
</item>
<item>
<title>Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39340828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241001141403&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The treatment benefits of the non-steroidal MRA finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a non-steroidal MRA may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. The sodium glucose-co-transporter-2 inhibitors (SGLT2i) and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: FINEARTS-HF was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction (LVEF) ≥40%. Baseline SGLT2i use was a prespecified subgroup. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. We first assessed for evidence of treatment heterogeneity based on baseline SGLT2i use. We further examined SGLT2i uptake during the trial and evaluated the treatment effects of finerenone accounting for baseline and during trial use of SGLT2i in time-varying analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6,001 participants, 817 (13.6%) were treated with an SGLT2i at baseline. During 2.6-years median follow-up, treatment with finerenone similarly reduced the risk of the primary outcome in participants treated with an SGLT2i (rate ratio 0.83; 95% confidence interval 0.60 to 1.16) and without an SGLT2i at baseline (rate ratio 0.85; 95% confidence interval 0.74 to 0.98); P<sub>interaction</sub>=0.76. In follow-up, 980 participants initiated SGLT2i, which was less frequent in the finerenone arm compared with placebo (17.7% vs. 20.1%; hazard ratio 0.86; confidence interval 0.76 to 0.97). Time-updated analyses accounting for baseline and subsequent use of SGLT2i did not meaningfully alter the treatment effects of finerenone on the primary endpoint.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The treatment benefits of the non-steroidal MRA finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a non-steroidal MRA may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39340828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241001141403&v=2.18.0.post9+e462414">39340828</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072055>10.1161/CIRCULATIONAHA.124.072055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39340828</guid>
<pubDate>Sat, 28 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Meike Brinker</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Markus Florian Scheerer</dc:creator>
<dc:creator>Andrea Lage</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-09-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure</dc:title>
<dc:identifier>pmid:39340828</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072055</dc:identifier>
</item>





























</channel>
</rss>